Regeneron Facing Securities Lawsuit Over Clinical Trial Disclosures

The complaint alleges that Regeneron violated the Securities Exchange Act by issuing false and misleading statements to the market. While the company projected confidence in the success of its Fianlimab-Libtayo trial and downplayed potential risks, the study eventually failed to reach its primary endpoint with statistical significance. Investors who suffered financial losses during this period are encouraged to reach out to the DJS Law Group before the September 14, 2026, deadline.

Legal representatives emphasize that shareholders do not need to be appointed as lead plaintiffs to participate in any eventual recovery. The firm, headed by David J. Schwartz, specializes in securities class actions and corporate governance litigation. Affected parties can contact their Eastchester, New York office at 914-206-9742 to discuss their eligibility and potential claims.